Last updated: March 31, 2024
Sponsor: University of Pavia
Overall Status: Active - Recruiting
Phase
N/A
Condition
N/ATreatment
Placebo
Berberol® K
Clinical Study ID
NCT06348550
BFMKP 01
Ages 18-70 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Overweight or obese subjects [according to body mass index (BMI)]
- Fasting plasma glucose value between 100 and 125 mg/dl, with impaired fasting glucoseor impaired glucose tolerance confirmed with oral glucose tolerance test (OGTT)
- Total cholesterol values ≥ 200 mg/dl
Exclusion
Exclusion Criteria:
- Patients with neoplastic and liver diseases, renal failure
- Patients with type 1 or 2 diabetes mellitus
- Pregnant or breastfeeding women
- Hypersensitivity to any of the ingredients
- Therapy with lipid-lowering drugs
- Use of products containing red yeast rice
Study Design
Total Participants: 120
Treatment Group(s): 2
Primary Treatment: Placebo
Phase:
Study Start date:
November 30, 2023
Estimated Completion Date:
September 30, 2024
Study Description
Connect with a study center
IRCCS Policlinico S. Matteo Foundation
Pavia, 27100
ItalyActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.